University/Organization, University of Sharjah
Collage of Medicine
UAE
Abstract
This study investigates the antibacterial efficacy of the Adam series compounds against multidrug-resistant (MDR) clinical isolates.
Gram positive and negative bacteria used in this investigation. HBEC-5i cells were obtained from the Adexbio and cultured in RPMI. At around 80 to 90 percent cell confluence. The cell cytotoxicity potential of Adam series was performed using Lactate dehydrogenase (LDH) assays procedure against HBEC-5i cells.
Adam series compounds exhibited bactericidal effects with exceptions noted for Adam 11S and Adam 16S against S. pneumoniae. Adam 10S displayed the highest antibacterial activity, eliminating 70% of bacteria, while Adam 17S and Adam 11S eliminated 50% and 35% of S. pneumoniae, respectively. Against S. pyogenes, all compounds demonstrated bactericidal activity, with Adam 1S exhibiting complete bacterial eradication and Adam 16S displaying an 84% killing effect. Similarly, antibacterial properties were observed against B. cereus, with Adam 1S achieving 100% bacterial elimination. Remarkable bactericidal effects were also noted against S. marcescens, E. coli K1, and S. enterica. MIC50 analysis revealed potent antibacterial activity of the compounds against S. marcescens and S. pyogenes. Additionally, lactate dehydrogenase assays indicated minimal cytotoxicity of the compounds on human microvascular endothelial cells, with Adam 10S, Adam 11S, Adam 16S, and Adam 17S demonstrating less than 20% cytotoxicity, while Adam 1S exhibited 32% cytotoxic effects against human cells. Adam series compounds have antibacterial efficacy and low cytotoxicity profile.